בית › סרטן הריאה › טנסי › Nashville
מחקרים קליניים עבור סרטן הריאה ב-Nashville, TN
40 מחקרים עבור סרטן הריאה מחפשים משתתפים באתרים ב-Nashville ובסביבתה (בטווח של כ-30 מייל). פתחו מחקר כדי לראות מי יכול להשתתף וכיצד ליצור קשר עם צוות המחקר.
טקסט רשמי של המחקר (באנגלית)
מגייסים משתתפים למחקר כאן? הציגו אותו בראש העמוד – $99 ל-30 ימים →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
מגייסשלב 1/2
- Sarah Cannon Research Institute, Nashville
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
מגייסשלב 2
- SCRI Oncology Partners, Nashville
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
מגייסשלב 1
- SCRI Oncology Partners, Nashville
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
מגייסשלב 3
- SCRI Oncology Partners, Nashville
A Study of PHN-012 in Patients With Advanced Solid Tumors
מגייסשלב 1
- PHN-012-001 Site, Nashville
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
מגייסשלב 3
- SCRI Oncology Partners - Tennessee, Nashville
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
מגייסשלב 1
- Sarah Cannon Research Institute- Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
מגייסשלב 3
- Sarah Cannon Research Institute, Nashville
- United States Oncology Regulatory Affairs Corporate Office, Nashville
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
מגייסשלב 3
- SCRI Oncology Partners, Nashville
- Tennessee Oncology, PLLC-Elliston Place Plaza Medical Oncology &Hematology, Nashville
- Tennessee Oncology, PLLC - Saint Thomas West, Nashville
- ועוד 3
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
מגייסשלב 2
- Sarah Cannon Research Institute, Nashville
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
מגייסשלב 2
- Research Site, Nashville
- Research Site, Nashville
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
מגייסשלב 2/3
- Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
מגייסשלב 2/3
- Tennessee Oncology, Nashville
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
מגייסשלב 1/2
- Sarah Cannon Research Institue, Nashville
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
מגייסשלב 1/2
- Tennessee Oncology, PLLC, Nashville
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
מגייסשלב 1/2
- Sarah Canon Research Institute (SCRI) Oncology Partners, Nashville
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
מגייסשלב 1
- Sarah Cannon Research Institute, Nashville
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
מגייסשלב 1
- Sarah Cannon Research Institute, Nashville
- SCRI Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
מגייסשלב 3
- Tennessee Oncology, Nashville
- USO - US Oncology Research Network, Nashville
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
מגייסשלב 1
- SCRI Oncology Partners, Nashville
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
מגייסמחקר תצפיתי
- Vanderbilt-Ingram Cancer Center, Nashville
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
מגייסשלב 1/2
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
מגייסשלב 1
- Xencor Investigative Site, Nashville
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
מגייסשלב 1/2
- Tennessee Oncology, Nashville
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
מגייסשלב 1
- Sarah Cannon, SCRI Oncology Partners, Nashville
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
מגייסשלב 1/2
- Vanderbilt University Medical Center, Nashville
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
מגייסשלב 1
- Research Site, Nashville
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
מגייסשלב 1
- Sarah Cannon Research Institute, Nashville
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
מגייסשלב 1/2
- Sarah Cannon Research Institute, Nashville
Molecular Predictors of Cancer in Patients at High Risk of Lung Cancer
מגייסמחקר תצפיתי
- Vanderbilt-Ingram Cancer Center, Nashville
- Veterans Affairs Medical Center - Nashville, Nashville
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
מגייסשלב 1/2
- SCRI Oncology Partners, Nashville
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
מגייסשלב 1
- SCRI Oncology Partners, Nashville
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
מגייסשלב 1
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
- Vanderbilt University Medical Center, Nashville
EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing
מגייסשלב 4
- Vanderbilt University/Ingram Cancer Center, Nashville
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
מגייסמחקר תצפיתימתנדבים בריאים מוזמנים
- Vanderbilt-Ingram Cancer Center, Nashville
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
מגייסשלב 1
- Sarah Cannon Research Institute (SCRI), Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
מגייסמחקר תצפיתי
- Massive Bio SYNERGY-AI site, Nashville
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
מגייסשלב 1/2
- Tennessee Oncology, Nashville
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
מגייסשלב 1/2
- Vanderbilt University/Ingram Cancer Center, Nashville
Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation
מגייסשלב 1/2
- Vanderbilt University/Ingram Cancer Center, Nashville
מחקרים עבור סרטן הריאה בערים אחרות
- Houston, TX78 מחקרים
- Boston, MA62 מחקרים
- New York City, NY60 מחקרים
- Los Angeles, CA45 מחקרים
- Arlington, VA41 מחקרים
- Washington, DC41 מחקרים
- Chicago, IL41 מחקרים
- Baltimore, MD40 מחקרים
- St. Louis, MO39 מחקרים
- Columbus, OH37 מחקרים
- Philadelphia, PA36 מחקרים
- Seattle, WA33 מחקרים
מחקרים אחרים ב-Nashville
- סרטן ריאות לא תא קטן97 מחקרים
- סרטן השד81 מחקרים
- סרטן גרורתי70 מחקרים
- סרטן המעי הגס והחלחולת69 מחקרים
- סרטן (כל הסוגים)65 מחקרים
- סרטן השחלות49 מחקרים
- סרטן הערמונית43 מחקרים
- קרצינומה קשקשית של ראש וצוואר39 מחקרים
- סרטן הלבלב39 מחקרים
- סרטן אנדומטריאלי38 מחקרים
- מלנומה33 מחקרים
- מיאלומה מרובה32 מחקרים
מקור: ClinicalTrials.gov, המידע אוחזר בתאריך 6 באוק׳ 2026. כל מחקר מגדיר את קריטריוני ההשתתפות שלו; צוות המחקר קובע מי יכול להשתתף.